Gilead Sciences, Inc. (GILD) stock price, news and key stats

Price

Last close as of Sep 16, 2026. Delayed data; not a live quote.

Previous close

$146.30

Open

$146.58

Day range

$146.12 – $149.30

Volume

5.2M

About Gilead Sciences, Inc.

Latest GILD news

• A onetime Gilead exec's novel startup eyes $1B IPO valuation
  IPO & M&A · Sep 15, 2026

  A new biotech startup, founded by a former Gilead Sciences executive, is poised to launch an initial public offering (IPO) that could reach a valuation of $1 billion. The company, which specializes in developing innovative therapies for immune-mediated diseases and cancer, plans to begin trading on the Nasdaq exchange this Friday under the ticker symbol ETRA. This move highlights the growing investor interest in the biotech sector, particularly in companies focused on addressing significant unmet medical needs. The anticipated IPO comes at a time when the market for biotech offerings has shown signs of recovery, following a challenging period characterized by regulatory hurdles and economic uncertainty. Investors are increasingly looking for opportunities in companies that can demonstrate a strong pipeline of drug candidates and potential for substantial market impact. If successful, this IPO could not only bolster the company's financial resources but also signal renewed confidence in the biotech industry, potentially attracting further investments in similar firms.

• Steady stream of crossover rounds stock biotech’s IPO pipeline
  IPO & M&A · Sep 9, 2026

  The biotechnology sector is experiencing a resurgence in initial public offerings (IPOs), driven by a steady influx of crossover funding rounds that have bolstered investor confidence. In recent months, public investors have shown renewed interest in biotech firms, paving the way for a series of anticipated public debuts. This renewed enthusiasm is reflected in the increasing number of companies successfully securing crossover investments, which typically involve both private and public investors, thereby enhancing their market readiness. The implications for the market are significant, as a robust IPO pipeline can attract further investment into the biotech sector, potentially leading to a more favorable environment for innovation and development. As companies prepare for their public offerings, the influx of capital from crossover rounds not only strengthens their financial positions but also signals to other investors that there is a viable path to profitability in the sector. This trend may encourage additional firms to pursue IPOs, further stimulating market activity and possibly leading to a competitive landscape that benefits both investors and consumers through accelerated advancements in biotechnology.

• There are some tremendous healthcare companies in bull market mode, says Jim Cramer
  Market Outlook · Sep 8, 2026

  Jim Cramer, the host of CNBC's "Mad Money," has highlighted a selection of healthcare companies that are currently thriving in what he describes as a bull market. Cramer emphasized that while artificial intelligence continues to capture headlines, investors should not overlook the robust performance and potential of healthcare stocks. He pointed to several firms that are not only showing strong earnings but also exhibiting resilience amid broader market fluctuations. Cramer’s analysis suggests that the healthcare sector is well-positioned for growth, driven by factors such as an aging population, increasing demand for innovative treatments, and advancements in biotechnology. This positive outlook could lead to increased investment in these companies, potentially boosting stock prices and attracting institutional interest. As investors seek to diversify their portfolios beyond tech-driven stocks, Cramer’s insights may encourage a shift towards healthcare, which could further enhance the sector's momentum in the coming months.

• Enhanced FDA-SEC Collaboration: How Life Sciences Companies Think About Disclosure, Insider Trading, and Prediction Markets
  Financial Regulation · Sep 8, 2026

  On August 31, 2026, the U.S. Securities and Exchange Commission (SEC) and the Food and Drug Administration (FDA) announced a new Memorandum of Understanding (MOU) aimed at enhancing collaboration between the two agencies. This initiative is expected to significantly impact how life sciences companies approach disclosure practices, insider trading, and prediction markets. By fostering a more integrated regulatory environment, the agencies aim to improve the transparency and accuracy of information provided to investors regarding drug approvals and clinical trial results. The MOU signals a proactive stance by regulators to address the complexities of the life sciences sector, where timely and accurate disclosures are critical for investor decision-making. As the FDA continues to evaluate new therapies and treatments, the SEC's involvement will likely lead to stricter scrutiny of disclosures related to clinical outcomes and potential market-moving events. This heightened oversight could deter insider trading and promote fairer market practices, as companies will need to ensure compliance with both agencies' standards. Market implications are substantial, as enhanced regulatory scrutiny may lead to increased volatility in life sciences stocks, particularly around key FDA announcements. Companies will need to adopt more rigorous disclosure protocols to mitigate risks associated with non-compliance. Investors should prepare for a landscape where information asymmetry is reduced, potentially leading to more informed trading strategies and a shift in how market participants assess the value of biotech and pharmaceutical firms.

• Novartis’s failed trial for cholesterol drug leads to broad biopharma stock selloff
  MarketWatch · Sep 8, 2026

  Shares of Novartis plummeted over 3% on Monday following the disappointing results of a pivotal trial for its cholesterol drug, which aimed to lower lipoprotein(a) or Lp(a) levels to reduce cardiovascular risks. The failure of this trial not only undermines Novartis's strategy but also raises concerns about the broader viability of Lp(a) targeting therapies in the biopharmaceutical sector. Investors had anticipated significant advancements in this area, making the trial results particularly impactful. The fallout from Novartis's announcement extended beyond its own stock, triggering a selloff across the biopharma industry as market participants reevaluated the potential of similar treatments from other companies. The collective market response reflects a growing skepticism towards the efficacy of Lp(a) lowering strategies, which had garnered considerable attention and investment. Analysts suggest that this could lead to a reevaluation of research and development priorities within the sector, as companies may now face increased pressure to demonstrate the viability of their cardiovascular drug pipelines.

• AI will help find cure for cancer ‘within our lifetimes’, says Arm Holdings chief
  Guardian Business · Sep 8, 2026

  Arm Holdings CEO Rene Haas has expressed optimism that advancements in artificial intelligence (AI) could lead to significant breakthroughs in cancer treatment within the next few decades. Speaking at a recent industry conference, Haas highlighted the potential of AI to analyze vast datasets, identify patterns, and accelerate drug discovery processes, which could ultimately result in more effective therapies for various cancer types. This assertion comes at a time when the intersection of technology and healthcare is garnering increased attention from investors and researchers alike. The integration of AI in medical research not only promises to enhance the efficiency of clinical trials but also to personalize treatment options for patients. As companies like Arm, which specializes in semiconductor technology, continue to innovate, the implications for the biotech sector are profound. Investors may see opportunities in firms that leverage AI to develop new treatments, potentially reshaping the landscape of cancer care. Market analysts are closely watching developments in this area, as the successful application of AI in oncology could lead to significant financial returns for tech and pharmaceutical companies alike. As the healthcare industry increasingly embraces digital transformation, the collaboration between AI firms and biotech companies may pave the way for groundbreaking advancements, making the prospect of curing cancer more attainable than ever before.

• Ulcerative Colitis Market Outlook: 5 Late-Stage Drug Candidates to Watch
  Market Outlook · Sep 7, 2026

  The ulcerative colitis market is poised for significant growth, with projections estimating its value to reach USD 15.99 billion by 2033, up from USD 10.16 billion in 2026, reflecting a compound annual growth rate (CAGR) of 6.7%. This expansion is largely driven by the increasing prevalence of the disease and the ongoing development of innovative therapies. Currently, the market is dominated by anti-TNF therapies, but a new wave of late-stage drug candidates is set to reshape treatment paradigms. Among the five late-stage drug candidates to watch are promising therapies that target various mechanisms of action, including integrins and JAK inhibitors. These candidates are expected to offer improved efficacy and safety profiles compared to existing treatments, which primarily include 5-aminosalicylic acid (5-ASA) therapies and corticosteroids. As these new therapies progress through Phase 3 and Phase 4 trials, their potential market entry could lead to increased competition and a shift in treatment strategies for patients with moderate to severe ulcerative colitis. The anticipated launch of these late-stage candidates is likely to impact market dynamics significantly, as healthcare providers and patients seek more effective and targeted treatment options. As the landscape evolves, pharmaceutical companies are expected to invest heavily in research and development to capitalize on the growing demand for ulcerative colitis therapies, ultimately enhancing patient outcomes and driving market growth.

• Gilead Sciences Just Won Its Third FDA Approval in Less Than 4 Months. Is the Stock Still Underrating This Turnaround Play?
  Yahoo Finance · Sep 5, 2026

  Gilead Sciences has recently secured its third FDA approval in less than four months, further solidifying its strategy to diversify beyond its traditional HIV treatments into oncology and immunology. The latest approval, which pertains to a novel therapy aimed at treating a specific type of cancer, underscores the company's commitment to expanding its product pipeline and addressing unmet medical needs in these high-growth areas. This rapid succession of approvals could signal a significant turnaround for Gilead, which has faced scrutiny over its reliance on HIV drugs in a competitive market. Market analysts are closely watching Gilead's stock performance in light of these developments. While the company’s shares have seen some upward movement following the approvals, many investors remain skeptical about whether the stock fully reflects the potential of its new therapies. The oncology and immunology markets are projected to grow substantially, and Gilead's recent successes could position it favorably against competitors. However, the company must demonstrate sustained revenue growth from these new products to alleviate concerns about its long-term viability. As Gilead continues to innovate and expand its therapeutic offerings, the implications for its stock could be significant. If the newly approved therapies gain traction in the market, they could contribute to a more robust revenue stream, potentially driving the stock higher. Investors will be keenly observing upcoming earnings reports and market reception of these therapies to gauge whether Gilead's turnaround narrative is gaining traction or if it remains undervalued in the eyes of the market.

• SEC, FDA sign info-sharing agreement as a ‘signal to the market’ on insider trading
  Financial Regulation · Sep 2, 2026

  The Securities and Exchange Commission (SEC) and the Food and Drug Administration (FDA) have formalized a three-year information-sharing agreement aimed at enhancing regulatory oversight and enforcement against insider trading, particularly in the pharmaceutical sector. This collaboration is expected to bolster the SEC's ability to detect and address potential insider trading activities that may arise from non-public information related to drug approvals and other FDA actions. Market analysts view this agreement as a significant signal to investors and companies within the pharmaceutical industry, indicating that regulatory scrutiny will intensify. By facilitating the exchange of critical information between the two agencies, the SEC and FDA aim to create a more transparent environment, potentially deterring illicit trading practices that can undermine market integrity. As a result, pharmaceutical stocks may experience increased volatility as investors reassess the risks associated with insider trading and regulatory compliance. The implications of this agreement extend beyond mere enforcement; it also highlights a growing recognition of the interconnectedness between regulatory bodies in safeguarding market integrity. As the SEC and FDA enhance their collaboration, companies in the biotech and pharmaceutical sectors may need to implement more robust compliance measures to navigate the heightened scrutiny, which could lead to increased operational costs. Overall, this partnership underscores the commitment of both agencies to uphold fair market practices and protect investors from the risks associated with insider trading.

• SEC and FDA sign 3-year market integrity pact
  Financial Regulation · Sep 1, 2026

  The U.S. Securities and Exchange Commission (SEC) and the Food and Drug Administration (FDA) have entered into a three-year agreement aimed at enhancing market integrity, particularly in sectors where financial and health regulations intersect. This unprecedented collaboration seeks to streamline the regulatory process for companies involved in biotechnology and pharmaceuticals, ensuring that financial disclosures align with the safety and efficacy of medical products. Under this pact, the two agencies will share data and insights more effectively, potentially reducing the time it takes for new drugs and therapies to reach the market. This could lead to increased investor confidence in biotech firms, as clearer regulatory pathways may mitigate risks associated with compliance and market volatility. Market analysts predict that this collaboration could stimulate investment in the biotech sector, as firms may find it easier to navigate the complex regulatory landscape. The agreement also underscores the growing recognition of the need for coordinated oversight in an increasingly interconnected financial and healthcare environment. As the SEC and FDA work together, stakeholders will be closely monitoring the implications for market dynamics, particularly how this partnership may influence stock valuations and investment strategies in the life sciences sector.

All 34 articles in the app →

Index membership

• S&P 500 · Health Care
• Nasdaq-100 · Health Care

Related Health Care stocks

• AAgilent Technologies
• ABBVAbbVie
• ABTAbbott Laboratories
• ALGNAlign Technology
• AMGNAmgen
• BAXBaxter International
• BDXBecton Dickinson
• BIIBBiogen